Sumitomo Mitsui DS Asset Management Company Ltd Boosts Stake in Danaher Co. (NYSE:DHR)

Sumitomo Mitsui DS Asset Management Company Ltd lifted its holdings in shares of Danaher Co. (NYSE:DHR) by 1.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 78,290 shares of the conglomerate’s stock after buying an additional 778 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd’s holdings in Danaher were worth $21,766,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the business. Ellsworth Advisors LLC bought a new position in Danaher during the third quarter valued at approximately $223,000. Compass Wealth Management LLC boosted its stake in shares of Danaher by 6.5% in the 3rd quarter. Compass Wealth Management LLC now owns 25,973 shares of the conglomerate’s stock worth $7,221,000 after buying an additional 1,585 shares during the last quarter. Good Life Advisors LLC bought a new stake in shares of Danaher in the third quarter worth $217,000. Naviter Wealth LLC increased its position in Danaher by 3.2% during the third quarter. Naviter Wealth LLC now owns 8,535 shares of the conglomerate’s stock valued at $2,375,000 after acquiring an additional 267 shares during the last quarter. Finally, Hengehold Capital Management LLC lifted its holdings in Danaher by 11.1% in the third quarter. Hengehold Capital Management LLC now owns 1,796 shares of the conglomerate’s stock valued at $499,000 after acquiring an additional 180 shares during the period. 79.05% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on DHR shares. TD Cowen upped their price target on shares of Danaher from $290.00 to $310.00 and gave the company a “buy” rating in a research report on Wednesday, July 24th. Leerink Partners lifted their price target on shares of Danaher from $275.00 to $280.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 24th. Bank of America boosted their price objective on shares of Danaher from $270.00 to $275.00 and gave the company a “neutral” rating in a research report on Wednesday, July 24th. Wells Fargo & Company initiated coverage on Danaher in a research report on Tuesday, August 27th. They set an “equal weight” rating and a $280.00 target price on the stock. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $300.00 price target on shares of Danaher in a research report on Friday, September 6th. Seven equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $282.12.

Insider Buying and Selling at Danaher

In related news, SVP Brian W. Ellis sold 9,600 shares of the stock in a transaction dated Thursday, July 25th. The shares were sold at an average price of $275.16, for a total value of $2,641,536.00. Following the completion of the transaction, the senior vice president now owns 20,230 shares of the company’s stock, valued at approximately $5,566,486.80. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, SVP Georgeann Couchara sold 952 shares of the firm’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the sale, the senior vice president now owns 4,212 shares in the company, valued at approximately $1,130,374.44. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Brian W. Ellis sold 9,600 shares of the company’s stock in a transaction dated Thursday, July 25th. The shares were sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the transaction, the senior vice president now owns 20,230 shares in the company, valued at $5,566,486.80. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 39,659 shares of company stock worth $11,042,433 over the last 90 days. 11.10% of the stock is owned by insiders.

Danaher Stock Up 1.5 %

DHR opened at $272.01 on Friday. The company has a market capitalization of $201.47 billion, a PE ratio of 46.10, a price-to-earnings-growth ratio of 4.49 and a beta of 0.83. The firm has a 50-day simple moving average of $270.60 and a two-hundred day simple moving average of $259.73. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33. Danaher Co. has a 52 week low of $182.09 and a 52 week high of $281.70.

Danaher (NYSE:DHR) last released its quarterly earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, beating the consensus estimate of $1.57 by $0.15. The business had revenue of $5.74 billion during the quarter, compared to analysts’ expectations of $5.59 billion. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The firm’s revenue for the quarter was down 2.9% compared to the same quarter last year. During the same quarter last year, the business posted $2.05 EPS. Analysts forecast that Danaher Co. will post 7.59 earnings per share for the current fiscal year.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Friday, September 27th will be paid a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a yield of 0.40%. The ex-dividend date is Friday, September 27th. Danaher’s payout ratio is 18.31%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.